Abstract:Aim: To discover novel ligands of estrogen receptor (ER) β using pharmacophore mapping and structure-based screening. Methods: A computer-aided strategy combining pharmacophore mapping and structure-based screening was used to screen the Maybridge and Enamine databases. Yeast two-hybrid (Y2H) assay was used to detect the activity and selectivity of the chosen compounds. The transcriptional activities of the chosen compounds were demonstrated with luciferase reporter assays. The anti-proliferative effects of ER antagonists against MCF-7 and MDA-MB-231 breast cancer cells were examined using MTT assay, and the mechanisms of action were analyzed with flow cytometry analysis and Western blotting. Results: Through in silico screen, 95 compounds were chosen for testing in Y2H assay, which led to 20 potent ligands, including 10 agonists, 8 antagonists and 2 partial agonists with EC 50 or IC 50 values at μmol/L. Furthermore, 6 agonists exhibited absolute selectivity for ERβ, and 3 agonists showed higher selectivity for ERβ. The agonists 1g and 1h (10, 25, and 50 μmol/L) dose-dependently increased ER transcriptional activities, whereas the antagonists 2a and 2d (10, 25, and 50 μmol/L) caused dose-dependent inhibition on the activities. The antagonists and partial agonists at 100 μmol/L suppressed the proliferation of ERα positive MCF-7 cells and ERβ positive MDA-MB-231 cells, but were more effective against MDA-MB-231 cells. Treatment of MDA-MB-231 cells with antagonists 2a and 2d (25 and 50 μmol/L) dose-dependently increased the population of cells in the S phase. Both 2a and 2d treatment dose-dependently decreased the expression levels of cyclin A and CDK2. Meanwhile, the downregulation of cyclin E was only caused by 2d , while 2a treatment did not cause significant changes in the protein levels of cyclin E. Conclusion: The selective ligands discovered in this study are promising drug candidates to be used as molecular probes to explore the differences between ERα and ERβ.

Structural Insights into the Specificity of Ligand Binding and Coactivator Assembly by Estrogen-Related Receptor Β

3d-Qsar And Docking Studies Of Estrogen Compounds Based On Estrogen Receptor Beta

Activation of ERβ Hijacks the Splicing Machinery to Trigger R-loop Formation in Triple-Negative Breast Cancer

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Computational insights into the mechanism of ligand unbinding and selectivity of estrogen receptors.

Structure of a Biologically Active Estrogen Receptor-Coactivator Complex on DNA.

Insights into the Interaction Mechanisms of Estrogen-Related Receptor Alpha (errα) with Ligands Via Molecular Dynamics Simulations

Molecular Docking, Molecular Dynamics Simulation, and Structure-Based 3D-QSAR Studies on the Aryl Hydrocarbon Receptor Agonistic Activity of Hydroxylated Polychlorinated Biphenyls.

Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.

ERR-10: a new repressor in transcriptional signaling activation of estrogen receptor-α

Structural Studies With Coactivators For The Estrogen Receptor

Progress in study of selective ERβ ligands

Computational Insights into the Interaction Mechanisms of Estrogen‐related Receptor Alpha with Endogenous Ligand Cholesterol

LARMD: Integration of Bioinformatic Resources to Profile Ligand-Driven Protein Dynamics with a Case on the Activation of Estrogen Receptor.

Computational investigation of the interaction mechanism between the estrogen related receptor alpha and its agonists

Homology modeling,refining and validating of estrogen receptor α36

In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using 3D-QSAR and Molecular Docking

Selective Ligands of Estrogen Receptor Β Discovered Using Pharmacophore Mapping and Structure-Based Virtual Screening.

Steroid Receptor-Coregulator Transcriptional Complexes: New Insights from CryoEM

Identification of New Small-Molecule Inducers of Estrogen-related Receptor Α (errα) Degradation

Structural Basis of Inhibition of ERα-Coactivator Interaction by High-Affinity N-Terminus Isoaspartic Acid Tethered Helical Peptides.